• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fractyl Health forms task force to understand root causes of type 2 diabetes

November 2, 2022 By Sean Whooley

Fractyl-Logo-CMYK-June2021-02Fractyl Health announced today that it created the Erase T2D task force to research type 2 diabetes in the hopes of “erasing” the condition.

The academic-industry scientific partnership aims to advance research on the role of the gut in metabolic disease. This, in turn, could catalyze future discoveries on understanding and erasing type 2 diabetes.

As part of the task force, Lexington, Massachusetts-based Fractyl announced the initiation of its first two research projects. It began programs with professor Alan Cherrington at Vanderbilt University and professor Randy Seeley at the University of Michigan.

Both scientific research initiatives seek to establish new evidence on nutrient sensing and signaling mechanisms in the duodenum. Fractyl develops the Revita duodenal mucosal resurfacing (DMR) procedure in the hopes of reversing type 2 diabetes. The company said it hopes the collaboration brings a deeper understanding of the relationship between a dysfunctional duodenum and the onset and progression of type 2 diabetes.

About the studies

Cherrington’s study focuses on the gut-derived signaling pathways central to type 2 diabetes development and progression.

“If the development of duodenal dysfunction as a consequence of high fat and sugar diets is an important event in the development of T2D, we need to try to understand which duodenal changes could represent key causal steps in metabolic dysregulation and diabetes pathogenesis,” said Cherrington.

Seeley’s study centers around establishing a rodent model of duodenal mucosal disruption. This helps to define the mechanism of action of therapies targeting the duodenal mucosa.

“I am confident that we are taking the first steps in gaining a deeper understanding of the processes in the gut that lead to metabolic disease,” said Seeley. “This will enable us to identify precursors and therefore ultimately build increasingly effective therapeutic approaches that could lead to a metabolic reset in patients with T2D.”

Fractyl added that it “is enthusiastic” to begin the effort with academic partners representing “icons” in the field.

“Our ambition is to support the deep science that will lead to a greater understanding of the root causes of T2D,” said Dr. Harith Rajagopalan, co-founder and CEO of Fractyl Health. “We know these studies are the beginning of a journey and will lead to findings — and more questions — we can use to define our next steps in the process of discovery.”

Filed Under: Business/Financial News, Diabetes, Featured, Surgical Tagged With: Fractyl Health

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS